Breast cancer among HIV infected individuals from the ONCOVIH study, in France: Therapeutic implications
Menée en France, cette étude prospective transversale "ONCOVIH" évalue la prévalence et le risque de cancer du sein chez des patientes infectées par le VIH, ainsi que les traitements reçus
The cross-sectional ONCOVIH study prospectively enrolled HIV-infected adults and children with newly diagnosed malignancies in France in 2006. We report the characteristics HIV-infected patients with breast cancer from the ONCOVIH study. Standardised questionnaires included characteristics of HIV infection and malignancy. Survival was estimated using Kaplan–Meier estimates. Overall, 21 patients with breast cancer (two men and 19 women) were included with a median age of 43.8years, (range: 30.1–65.5). At time of tumour diagnosis, the median CD4 count was 384/mm3 (range: 180–1039) the median duration of known seropositivity 7.7years (range: 0–20.3); 14 patients were under combined antiretroviral therapy for a median duration of 5.7years (range: 1.1–10.6), of whom 11 had a controlled viral load (<500copies/mL). The median tumour size was 1.8cm (range: 1.0–7.0). In women, 17 (89.5%) had invasive ductal carcinoma, 17 (89.5%) with HER2 negative receptors, 8 (42.1%) with ER+ expression, and 7 (36.8%) with PR+ expression. A majority of women received chemotherapy (73.7%), surgery (68.4%) and radiotherapy (57.9%). Their one-year survival rate was estimated as 77.8% (95%confidence interval (CI): 58.6–97.0%). We discuss the risk of breast cancer in infected patients, and the importance of taking into account the different contributing factors for breast cancer in HIV-infected individuals.
http://linkinghub.elsevier.com/retrieve/pii/S0959804912004339?showall=true